The Effects of Zataria Multiflora Boiss (Shirazi's Thyme) on Nonalcoholic Fatty Liver Disease (ThymeLiv)
The Effects of Zataria Multiflora Boiss (Shirazi's Thyme) on Biochemical Markers and Imaging Studies of Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Fars
-
Shiraz, Fars, Iran, Islamic Republic of
- Shahid Motahhari Clinic, Shiraz University of Medical Sciences
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age: 20-65 years
- Body mass index: 18-35 kg/m2
- Serum ALT level: >45 U/Lit. in Males, >29 U/Lit. in Females
- Grade >=1 fatty liver in liver sonography
Exclusion Criteria:
- Pregnancy and Lactation
- Acute or chronic liver failure
- Acute or chronic renal failure
- Autoimmune or viral hepatitis
- Wilson's disease
- Diabetes mellitus
- Alcoholism
- Malignancy
- Hypothyroidism or hyperthyroidism
- Drug used in last three months: OCP, metformin, vitamin E, ursodeoxycholic acid, glucocorticoids, thiazolidenediones.
- History of allergic reactions to Thyme
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Thyme
Zataria multiflora Boiss powder capsule 350 mg twice daily for 3 months
|
Thyme capsule 350 mg twice daily
Other Names:
|
|
Placebo Comparator: Placebo
Wheat powder capsule 350 mg twice daily for 3 months
|
Placebo capsule 350 mg twice daily
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in ALT (Alanin aminotransferase) level
Time Frame: 3 months
|
3 months
|
|
Change in grade of fatty liver in sonography by use of Saverymuttu Scoring System
Time Frame: 3 months
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Body weight
Time Frame: 3 months
|
3 months
|
|
Waist circumference
Time Frame: 3 months
|
3 months
|
|
Change in AST (Aspartate aminotransferase) level
Time Frame: 3 months
|
3 months
|
|
Fasting blood sugar (FBS)
Time Frame: 3 months
|
3 months
|
|
Change in Gama GT (γ-glutamyl transpeptidase) level
Time Frame: 3 monyhs
|
3 monyhs
|
|
Fasting insulin level
Time Frame: 3 months
|
3 months
|
|
Hip circumference
Time Frame: 3 months
|
3 months
|
|
Number of patients with adverse events
Time Frame: 4 months
|
4 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Mojtaba Heydari, MD, Research Center for Traditional Medicine & History of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
- Principal Investigator: Majid Nimruzi, MD, Research Center for Traditional Medicine & History of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
- Principal Investigator: Nasrin dokht Zamani, MD, Research Center for Traditional Medicine & History of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 94-7648
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.